NCT03805100: A trial that was reported late by Xbrane Biopharma AB
This trial has reported, although it was 259 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03805100 |
|---|---|
| Title | A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 19, 2019 |
| Completion date | May 11, 2021 |
| Required reporting date | May 11, 2022, midnight |
| Actual reporting date | Jan. 25, 2023 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 259 |